Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Using a sensitive luciferase immunoprecipitation system (LIPS) to detect HTLV-I/II seroindeterminates in Jamaica

  • 1,
  • 1,
  • 2,
  • 1 and
  • 1Email author
Retrovirology20118 (Suppl 1) :A249

https://doi.org/10.1186/1742-4690-8-S1-A249

  • Published:

Keywords

  • Spastic Paraparesis
  • Confirmatory Western Blot
  • Core Band
  • Infective Dermatitis
  • Antibody Detection Assay

Human T-cell Leukemia Virus type I (HTLV-I) infects an estimated 15-20 million persons worldwide. A number of diseases have been associated with this virus including adult T-cell leukemia/lymphoma (ATLL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HLTV-I uveitis, and HTLV-I–associated infective dermatitis. The screening process for HTLV-I among blood banks includes detection by an enzyme immunoassay (EIA) followed by a confirmatory western blot (WB). Seropositive results are defined by the presence of all core bands (p19, p24, and p53) as well as the band specific for recombinant HTLV-I Env glycoprotein. However, numerous cases have been documented in which a positive response was detected by ELISA, but WB displayed an incomplete banding pattern. These samples were then categorized as seroindeterminates. Using the LIPS assay, 60% of the 53 seroindeterminate samples previously screened by ELISA and WB displayed anti-HTLV-I Gag, Env or Tax antibody responses (based on 2 standard deviations above the mean value for the HTLV-I negative group). The LIPS assay was also able to detect anti-HTLV-I antibody responses in 6% of the 167 samples determined to be HTLV-I ELISA negative. A number of these samples were subsequently found to have an indeterminate WB pattern. Although the significance of these HTLV-I/II seroindeterminates is unclear, it may suggest a much higher prevalence of exposure to HTLV-I/II than previously estimated, as seroindeterminate samples may indicate exposure to the virus. The LIPS assay is a sensitive and high throughput antibody detection assay which may prove to be a useful tool in HTLV-I related clinical investigations.

Authors’ Affiliations

(1)
Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, USA
(2)
Division of Epidemiology, Food and Drug Administration, Silver Spring, MD, USA

Copyright

© Akahata et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement